The company has been asked by the Food & Drug Administration to perform a further clinical trial before it signs off the drug.
Motif therefore wants to arrange what’s called a Type-B meeting with the watchdog to discuss just which types of patient will take part in the new study along with its design.
It typically takes around 60 days from the time of request to schedule a face to face of this kind.
Along with the request, the company has also submitted an information package.
Motif chief executive Graham Lumsden said: “As we continue our discussions with potential US commercial partners and evaluate potential funding options for the iclaprim clinical programme, we expect to gain greater clarity from the Agency during the Type-B meeting on the pathway forward for iclaprim."
The FDA in an earlier discussion encouraged Motif to carry out a further trial to allay concerns over liver toxicity, which emerged following the submission of trial data from two phase III assessments of the drug.